ERBB2 and breast cancer: In our cohort, most (17/26) HER2 + tumours were ER+, but the BC deaths and the distant recurrences all occurred in the HER2+/ER− subgroup, while locoregional recurrences occurred equally in the HER2+/ER− and HER2+/ER+ groups (data not shown).